Human Epididymis Protein 4 for Differential Diagnosis Between Benign Gynecologic Disease and Ovarian Cancer: a Systematic Review and Meta-analysis

Overview

Journal Eur J Obstet Gynecol Reprod Biol

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2012 Dec 12

PMID 23228410

Citations 33

Authors

Jiaying Lin

Jinbao Qin

Voramon Sangvatanakul

Affiliations

Soon will be listed here.

Abstract

Objectives: Human epididymis protein 4 (HE4) is a new biomarker for the detection of ovarian cancer. The objective of this review was to assess by meta-analysis the overall diagnostic accuracy of HE4 assay in differentiating malignant ovarian tumors from benign gynecology diseases.

Study Design: The MEDLINE, EMBASE, and Cochrane Library databases were searched for studies published up to June 2012 that evaluated HE4 accuracy. Meta-analysis was used to calculate sensitivity, specificity, the positive likelihood ratio (PLR), the negative likelihood ratio (NLR) and the area under curve (AUC).

Results: A total of 11 studies with 3395 patients who fulfilled all inclusion criteria were considered in the analysis. No publication bias was found. HE4 had a pooled sensitivity of 0.74 (95% confidence interval (CI), 0.72-0.76) and a pooled specificity of 0.87 (95% CI, 0.85-0.89). Overall, the positive likelihood ratio was 8.04 (95% CI, 4.89-13.21) and the negative likelihood ratio was 0.27 (95% CI, 0.22-0.34). When HE4 was combined with CA125, the sensitivity was higher than that of HE4 alone at the expense of lower specificity.

Conclusions: The measurement of serum HE4 is a useful method for differential diagnosis between benign gynecologic disease and ovarian cancer.

Citing Articles

Advances and challenges in the use of liquid biopsy in gynaecological oncology.

Zhang Y, Tian L Heliyon. 2024; 10(20):e39148.

PMID: 39492906 PMC: 11530831. DOI: 10.1016/j.heliyon.2024.e39148.

Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.

Kikuchi Y, Shimada H, Yamasaki F, Yamashita T, Araki K, Horimoto K Int J Clin Oncol. 2024; 29(5):512-534.

PMID: 38493447 DOI: 10.1007/s10147-024-02497-0.

Comparison of Human Epididymis Protein 4, Cancer Antigen 125, and Ultrasound Prediction Model in Differentiating Benign from Malignant Adnexal Masses.

Bahadur A, Bhattacharya N, Mundhra R, Khoiwal K, Chawla L, Singh R J Midlife Health. 2024; 14(3):176-183.

PMID: 38312761 PMC: 10836431. DOI: 10.4103/jmh.jmh_77_23.

Radiomics nomogram for preoperative differentiation of early-stage serous borderline ovarian tumors and serous malignant ovarian tumors.

Yu X, Zou Y, Wang L, Yang H, Jiao J, Yu H Front Oncol. 2024; 13:1269589.

PMID: 38288103 PMC: 10822955. DOI: 10.3389/fonc.2023.1269589.

Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours among patients in Lagos, Nigeria.

Shittu K, Rabiu K, Akinola O, Ahmed S, Adewunmi A Ecancermedicalscience. 2023; 17:1568.

PMID: 37533954 PMC: 10393307. DOI: 10.3332/ecancer.2023.1568.